The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam, The Netherlands : Elsevier Science
      Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
    • Subject Terms:
      Breakthrough Infections* ; COVID-19*/prevention & control; Adult ; Aged ; Female ; Humans ; Middle Aged ; Young Adult ; Age Factors ; COVID-19 Vaccines/adverse effects ; Health Expenditures ; Hospitalization ; Retrospective Studies ; Vaccination ; Vaccine Efficacy ; Male
    • Abstract:
      Objectives: Although COVID-19 no longer constitutes a Public Health Emergency of International Concern, vaccination remains an important tool for reducing disease burden and mitigating future outbreaks. However, little is known about the impact of vaccination on medical expenditures and hospitalization duration after breakthrough infection. This study aimed to examine this impact during the Delta wave in Japan.
      Methods: This retrospective study was conducted using medical care claims data, vaccination records, and COVID-19-related information. COVID-19 cases in three municipalities were categorized into two age groups: 20-64 years and ≥65 years. For each group, we constructed linear regression models with a generalized estimating equation. We calculated the risk ratios (RRs) and 95% confidence intervals (CIs) of COVID-19 vaccination for total medical expenditures and hospitalization duration after adjusting for sex, comorbidities, and municipality.
      Results: We analyzed 618 cases aged 20-64 years (mean age: 38.4 years, women: 45.1%) and 208 cases aged ≥65 years (76.4 years, 53.8%). The RRs (95% CIs) of vaccination for total medical expenditures were 0.53 (0.44-0.64) in the 20-64 years age group and 0.51 (0.39-0.66) in the ≥65 years age group. Next, the RRs (95% CIs) of vaccination for hospitalization duration were 0.59 (0.42-0.83) in the 20-64 years age group and 0.69 (0.49-0.98) in the ≥65 years age group.
      Conclusions: COVID-19 vaccination was associated with lower total medical expenditures and hospitalization duration after breakthrough infection, with a more pronounced effect in older persons.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
    • Contributed Indexing:
      Keywords: COVID-19 breakthrough infections; COVID-19 vaccines; Hospitalization duration; Medical expenditures
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20240206 Date Completed: 20240318 Latest Revision: 20240318
    • Publication Date:
      20240318
    • Accession Number:
      10.1016/j.vaccine.2024.01.082
    • Accession Number:
      38320932